Link Cell Therapies is an oncology biotechnology company founded in 2022 that leverages proprietary logic-gating technology to create CAR-T cells able to recognize combinations of tumor-specific antigens, minimizing on-target, off-tumor toxicity. Its lead program, LNK001, targets two antigens co-expressed in most renal cell carcinoma tumors and is expected to file an IND and begin Phase I dosing in 2026. A second program for colorectal cancer is slated for development-candidate selection in 2026 and human studies in 2027, with additional earlier-stage solid and liquid tumor programs in the pipeline. The company’s technology originates from research conducted at Stanford University by co-founders Dr. Robbie Majzner and Dr. Crystal Mackall. Based in South San Francisco, the firm collaborates with a network of scientific advisors and strategic partners to advance its therapies. Financially, Link has secured $92 million across seed and Series A financings, providing runway to progress its lead assets through early clinical development. No revenue or commercial products have been reported to date.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025